Document Detail

Low apoptotic activity in primary prostate carcinomas without response to hormonal therapy.
MedLine Citation:
PMID:  10948353     Owner:  NLM     Status:  MEDLINE    
Proliferative and apoptotic activities, as well as p53 protein expression, of ten untreated primary prostate carcinomas that showed extremely poor response to hormonal therapy (primary androgen independent prostate carcinomas) were compared with the stage- and grade-matched primary tumor specimens with favorable response to hormonal therapy (androgen dependent prostate carcinomas). The mean proliferative activity measured by Ki-67 immunohistochemistry was slightly higher in the primary androgen independent prostate carcinomas (8.70+/-5.24) than in the androgen dependent prostate carcinomas (7.09+/-2.68; p=0.27). The mean apoptotic activity by in situ end-labeling technique in the primary androgen independent prostate carcinomas (0.96+/-1.03) was less than half of that in the androgen dependent prostate carcinomas (2.75+/-0.98; p=0.0001). Ten percent of the androgen dependent prostate tumors showed p53 protein expression, whereas 30% of the primary androgen independent prostate tumors were immunopositive for p53 (p=0.30). In summary, we have shown that apoptotic activity in the primary androgen independent prostate carcinomas is significantly lower than in the matched androgen dependent prostate carcinomas while the proliferative activity remains unaffected. These results suggest that primary androgen independent prostate carcinomas may have genetic properties, such as inactivation of the p53 gene, that enable them to escape apoptosis caused by androgen ablation.
C Palmberg; I Rantala; T L Tammela; H Helin; P A Koivisto
Related Documents :
19548283 - Hesperidin suppressed proliferations of both human breast cancer and androgen-dependent...
9259393 - Identification of an exon 3 deletion splice variant androgen receptor mrna in human bre...
12570693 - Inhibitors of 17 beta-hydroxysteroid dehydrogenases.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Oncology reports     Volume:  7     ISSN:  1021-335X     ISO Abbreviation:  Oncol. Rep.     Publication Date:    2000 Sep-Oct
Date Detail:
Created Date:  2000-08-24     Completed Date:  2001-01-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  1141-4     Citation Subset:  IM    
Department of Surgery, Pietarsaari Hospital, FIN-68601 Pietarsaari, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Androgen Antagonists / therapeutic use
Androgens / physiology*
Antineoplastic Agents, Hormonal / therapeutic use
Apoptosis / physiology*
Cell Division / physiology
Middle Aged
Neoplasms, Hormone-Dependent / drug therapy,  pathology*
Prostatic Neoplasms / drug therapy,  pathology*
Survival Analysis
Tumor Suppressor Protein p53 / biosynthesis,  genetics,  immunology
Reg. No./Substance:
0/Androgen Antagonists; 0/Androgens; 0/Antineoplastic Agents, Hormonal; 0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed o...
Next Document:  Transplacental effects of a 15% olive-oil diet on chemically-induced tumorigenesis in offspring.